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ABSTRACT 
Background: Recently, high prevalence of cryofibrinogenaemia has been observed 
in plasma of untreated dermatitis herpetiformis (DH) patients, and the pathological 
IgA and TG3 deposits in the papillary dermis were found to co-localize with fibrin 
and fibrinogen. 
Objective: To study the fibrinolytic potential in plasma of untreated, dapsone and 
or/ gluten-free diet treated DH patients as well as the in vitro effect of dapsone on 
the fibrinolytic profile.  
Method: Plasma samples of 23 DH patients, 19 healthy subjects and 5 pemphigus 
vulgaris patients were investigated by a turbidimetric-clot lysis assay. Out of them 5 
DH plasma samples representing different fibrinolytic parameters, and 3 healthy 
controls were selected for parallel fibrin clot preparation. The clot fibrin structure 
was examined by scanning electron microscopy (SEM), and the diameters of 900 
fibrin fibres were determined in each clot. 
Results: A significantly prolonged clot lysis time was detected in untreated DH 
patients. The turbidity values of DH plasma clots indicated an altered fibrin 
structure that was also confirmed by SEM: significantly thicker fibrin fibers were 
observed in untreated, TG3 antibody positive DH patients compared to healthy 
controls, whereas the fiber diameters of dapsone-treated patients were similar or 
thinner than the control values. In line with the structural changes of fibrin, the 
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fibrinolytic profile of 5 DH patients under dapsone treatment approached the 
control values.  
Conclusion: This study revealed that the fibrinolytic potential was impaired in the 
plasma of untreated DH patients, whereas dapsone corrected the fibrinolytic 
defect. These data suggest a pathogenic role for plasma-derived factors in the 
development of skin symptoms and add a new aspect to the long-known beneficial, 
symptomatic effect of dapsone in active DH.  
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INTRODUCTION 
Dermatitis herpetiformis (DH) is a chronic blistering skin disease characterized by 
grouped pruritic papules, vesicles above the elbows, knees and buttocks, but acral 
purpuras are also common findings mostly on fingers or toes [[1], [2]]. Epidermal 
transglutaminase (TG3) is the major antigen of DH [3], and it forms insoluble 
aggregates with granular immunoglobulin A (IgA) depositions in the papillary 
dermis. On the other hand, very early observations evidenced an extravascular 
fibrinogen and fibronectin staining along the papillary IgA in DH [[4], [5], [6], [7]]. A 
preserved activity of TG3 within the cutaneous IgA-fibrinogen complexes was also 
detected recently [8]. 
DH develops in a subpopulation of patients with underlying gluten sensitive 
enteropathy, in whom transglutaminase 2 (TG2) and TG3 antibodies (AB) are 
typically present. The recent observation that untreated DH patients have a high 
prevalence of cryofibrinogenemia in plasma [9] prompted us to examine DH 
plasma samples as a possible source of skin deposited fibrinogen along with IgA 
and TG3. It has been shown previously that dapsone, the symptomatic treatment in 
DH, seems to decrease the amount of cryofibrinogen in vitro [10], but the exact 
mechanism of action is unknown. 
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The presence of plasma cryofibrinogen is indicating a temperature dependent 
pathology associated with the function of circulating fibrinogen. The clearance of 
cryofibrinogen aggregates is mediated probably by the same proteolytic 
mechanism as the resolution of intravascular fibrin clots, which are formed when 
plasma fibrinogen is converted to fibrin by thrombin. Fibrin monomers polymerize 
through non-covalent interactions and by isopeptide bond formation between the 
monomers. This clot formation/stabilization is a common phenomenon also in 
inflammation [[11], [12]]. The major route for elimination of fibrin clots is their 
proteolytic degradation by plasmin formed from plasma plasminogen by tissue 
plasminogen activator (tPA) [13] and this route is very sensitive to a variety of 
biomechanical, chemical and cellular factors [14]. 
In this study we investigated the plasma and serum of DH patients for their 
capacity to form and resolve fibrin clots and observed a decreased fibrinolytic 
potential associated with a modified fibrin structure, as well as a reversal of the 
fibrinolytic abnormalities by dapsone, an effective symptomatic therapeutic agent in 
DH.  
 
MATERIALS AND METHODS 
Patients and controls 
The diagnosis of DH was based on clinical symptoms, routine skin histology and 
on presence of granular IgA precipitates in the papillary dermis by direct 
immunofluorescence. In all DH patients the IgA type TG3 enzyme-linked 
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immunosorbent assay (ELISA) and in all DH patients and healthy subjects the IgA 
type TG2 ELISA and/or the endomysial AB (EMA) tests were also performed. None 
of the patients and healthy subjects had a selective IgA deficiency and none of 
them received therapy with known impact on the haemostatic system before or at 
evaluation.  
Twenty-three DH patients, 17 males and 6 females, mean age 41±13 years (range 
21-74) and 12 healthy controls, 6 males and 6 females, mean age 33±10 years 
(range 23-55) were enrolled in the turbidimetric clot-lysis assay study. Out of the 
total 23 DH patients the following subgroups were also selectively evaluated: a, 
7/23 untreated DH patients with skin symptoms (no gluten-free diet (GFD), no 
dapsone treatment) b, 5/23 under dapsone medication (3/5 also under intermittent 
GFD) c, 11/23 under continuous GFD (Table 1). Dapsone was given to patients 
who wanted to get rapid improvement or received the medication in other clinics.  
As a separate study 5 female pemphigus vulgaris patients (see above, Table 1) 
and 7 healthy subjects, 2 males and 5 females, mean age 44±18 years (range 25-
72 years) were examined by a turbidimetric clot-lysis assay. 
All procedures have been approved by the Semmelweis University Regional and 
Institutional Committee of Science and Research Ethics (88/2013.) and were in 
accordance with the Helsinki Declaration. All subjects gave an informed written 
consent to participate in this study.  
 
Direct immunofluorescence studies 
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The DIF was performed on 10 µm frozen sections of the patients’ skin using 
fluorescein isothiocyanate (FITC) conjugated, goat antihuman complement 3 (C3), 
IgA, IgG and IgM AB (Dako, Glostrup, Denmark). 
 
Serological markers 
EMA were measured by indirect immunofluorescence according to the 
manufacturer’s instructions (ImmuGlo IMMCO Diagnostics, Buffalo, NY). 
TG3 and TG2 IgA AB were tested in duplicate by commercial ELISA kits. The cut-
off value for the TG3 IgA ELISA (Immundiagnostik, Bensheim, Germany) was 22 
AU/ml, for TG2 IgA ELISA (Orgentec Diagnostika, Mainz, Germany) was 10 AU/ml 
according to the manufacturer’s instruction. 
 
Turbidimetric clot-lysis assay and the in vitro effect of dapsone 
This assay was described earlier [15]. Briefly: freshly, simultaneously prepared 
plasma and serum samples were analysed within 1 h after collection without 
freezing to avoid cryoprecipitation. Plasma clots were prepared with 5 µL thrombin 
(30 U/mL) added to a mixture of 50 µL citrated human blood plasma (collected in 
3.8% sodium citrate blood collection tube) and 50 µL 0.1 µg/ml tPA (Actilyse, 
Boehringer Ingelheim, Germany) in 10 mM HEPES-NaOH pH 7.4 buffer containing 
150 mM NaCl and 25 mM CaCl2. When serum clot lysis was examined, the 
HEPES buffer contained also 2 mg/ml fibrinogen (human, plasminogen-depleted, 
Calbiochem, LaJolla, CA). The course of clot formation and dissolution was 
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monitored by measuring the light absorbance at 340 nm (A340) at 37°C with a 
Zenyth 200rt microplate spectrophotometer (Anthos Labtec Instruments GmbH, 
Salzburg, Austria). The lysis time, defined as the time needed to reduce the 
turbidity of the clot to half-maximal value, was used as a quantitative parameter of 
the fibrinolytic activity, whereas the maximal turbidity (A340max) was an indicator of 
the fiber size of fibrin [16]. Higher turbidity indicates thicker fiber diameters and 
larger clot pores [[17], [18]]. 
Dapsone at 5 µg/ml [19] was applied directly to freshly prepared plasma samples of 
2 untreated DH patients (2 males, 68 and 74 years old, see Patient 22 and 23 in 
Table 1) and 2 healthy subjects (2 males, 29 and 39 years old) for 30 min prior the 
clotting in the fibrinolytic assay. 
 
Scanning electron microscope (SEM) imaging of plasma clots 
Four out of 34 plasma samples were selected for SEM according to their lysis-
curves (A340max values), Patient 1,2,3 (P1, P2, P3) (Table 1) and a healthy subject 
with average control turbidity. P1, who showed the highest A340max, was a TG2-TG3 
AB positive, untreated DH patient, P2, who showed the lowest A340max, was a TG2-
TG3 AB negative, dapsone and GFD treated DH patient and P3 with medium 
turbidity was a TG2 AB negative-TG3 AB positive, only dapsone treated DH patient 
(Fig. 2A, Table 1). SEM evaluation of fibrin from further 2 untreated, seronegative 
DH patients (P22, P23 in Table 1) and 2 healthy subjects were done to 
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characterize the fibrin structure before and after in vitro dapsone addition (see 
above).  
Plasma clots were prepared as described above for the clot-lysis assay (omitting 
tPA from the reaction mixture). Following 30-min clotting at 37°C, clots were fixed 
in 1 %(v/v) glutaraldehyde in 100 mM Na-cacodylate pH 7.2 buffer for 16 h. The 
fixed samples were dehydrated in a series of ethanol dilutions (20 – 96 %(v/v)), 1:1 
mixture of 96 %(v/v) ethanol/acetone and pure acetone followed by critical point 
drying with CO2 in E3000 Critical Point Drying Apparatus (Quorum Technologies, 
Newhaven, UK). The specimens were mounted on adhesive carbon discs, sputter 
coated with gold in SC7620 Sputter Coater (Quorum Technologies, Newhaven, 
UK) and images were taken with SEM EVO40 (Carl Zeiss GmbH, Oberkochen, 
Germany). 
 
Morphometric analysis of fibrin structure and statistical procedures 
SEM images of the four selected plasma clots according to the A340max values (Fig. 
1), and in a separate study clots from two more untreated DH patients and two 
healthy subjects (see above) were analysed to determine the diameter of the fibrin 
fibers using self-designed scripts running under the Image Processing Toolbox v. 
7.0 of Matlab 7.10.0.499 (R2010a) (The Mathworks, Natick, MA). For the diameter 
measurements a grid was drawn over the image with 10-15 equally-spaced 
horizontal lines and all fibers crossed by them were included in the analysis. The 
diameters were measured manually by placing the pointer of the Distance tool over 
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the endpoints of transverse cross-sections of 300 fibers from each image (always 
perpendicularly to the longitudinal axis of the fibers) and 3 images from each 
plasma sample were evaluated. The distribution of the measured fiber diameter 
data was analysed using an algorithm described previously to fit theoretical 
distributions to several empirical data sets [20]. The best fitted distributions for 
different samples were compared using Kuiper test and Monte Carlo simulation 
procedures. When a statistically significant difference between two distributions 
was established, the numerical characteristics of the central tendency and variance 
were considered to be statistically significant. The statistical evaluation of the lysis-
assay parameters (lysis time, A340max) was performed with Kolmogorov-Smirnov 
test (Statistical Toolbox 7.3 of Matlab). A p-value of less than 0.05 was considered 
statistically significant. 
 
RESULTS 
Turbidimetric clot-lysis assay and the in vitro effect of dapsone 
The fibrinolytic potential of clots formed from fresh blood plasma (fibrinogen rich 
samples) and from modified fresh serum (fibrinogen-free samples supplemented 
with normal human fibrinogen) was evaluated in 23 DH patients (7/23 untreated, 
5/23 treated with dapsone (3/5 also under intermittent GFD), 11/23 on continuous 
GFD) and in 12 healthy subjects by a turbidimetric lysis assay (Fig. 1). The plasma 
clot lysis time was significantly prolonged in the groups of untreated (n=7) as well 
as total DH patients (n=23) and their A340max values were significantly higher 
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compared to healthy subjects (Fig. 2). When lysis was evaluated in clots from sera 
of the same patients, supplemented with exogenous fibrinogen, no significant 
differences were detected neither in turbidity (A340max), nor in lysis time. 
Dapsone treatment in DH resulted in statistically significant differences in the 
plasma clot lysis time and A340max compared to the untreated patients, because the 
dapsone therapy shifted the parameters of the fibrinolytic profile towards the values 
of healthy subjects (Fig. 2A, 2C). A moderate (by 5-10 %), but statistically 
significant decrease in both A340max and lysis time was detected when dapsone at 5 
µg/ml was applied directly to plasma samples of 2 untreated DH patients for 30 min 
prior the clotting in the fibrinolytic assay (Table 2). It is noteworthy that GFD 
improved the fibrinolytic parameters of DH patients, but statistical differences 
persisted in both lysis time and A340max compared to healthy subjects (Fig. 2). The 
differences in the lysis of plasma clots from DH patients with and without dapsone 
therapy disappeared in serum studies when exogenous fibrinogen was added to 
serum samples (Fig. 2B, 2D). 
In another set of control experiments plasma clots from pemphigus vulgaris 
patients (n=5) showed no significant difference to plasma clots from healthy 
subjects (n=7), neither in A340max value (0.4603 ± 0.09 vs. 0.5688 ± 0.0658), nor in 
lysis time (103.1 ± 15.64 min vs. 87.9 ± 22.5 min), and these values were also 
normal in their fibrinogen-supplemented serum clots (A340max value 0.2551 ± 0.024 
vs. 0.253 ± 0.008, lysis time 56.2 ± 15.7 min vs. 59.2 ± 0.008 min) (Table 1). 
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Scanning electron microscope (SEM) imaging of plasma clots 
The altered A340max values observed in plasma clots from DH patients could be 
attributed either to variations in the fibrinogen concentration or to a modified fibrin 
structure. Because the fibrinogen levels of the examined plasma samples were 
within the normal range (1.5 - 4.5 g/l), we performed direct evaluation of the fibrin 
structure with SEM. The fibrin network from the untreated, TG2-TG3 AB positive 
P1 patient showed more convoluted and thicker fibers than the clot from the 
healthy subject. The fibrin in plasma clots of the TG2-TG3 AB negative, dapsone 
treated P2 patient on GFD presented with thinner fiber diameters and loose larger 
pores than P1 or the healthy subject (Fig. 3A). This visual impression for existing 
differences in fibrin structure was further substantiated by quantitative analysis of 
the fiber diameter in plasma clots (Fig. 3B): The median fiber diameter in the 
plasma clots of the untreated P1 (137.9 nm) was larger, as compared to the fibrin 
of a healthy subject (median 114.2 nm, p<0.001). The fibrin fibers in plasma clots 
from dapsone-treated patients, either under GFD (P2), or without diet (P3) were 
either thinner (P2) or identical in size compared to the control (Fig. 3B). In a 
separate study SEM evaluation of fibrin from further 2 untreated DH patients and 2 
healthy subjects confirmed the trend of fiber thickening in DH (median of 113.0 and 
115.6 nm versus 74.5 and 113.0 nm). Direct application of dapsone at 5 µg/ml for 
30 min prior clotting resulted in a significant reduction in fiber diameter in both DH 
patients and healthy subjects (to median values in the range 58.0 – 78.8 nm). 
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DISCUSSION  
Based on the recent findings of high prevalence of cryofibrinogen in DH patients 
[9], we hypothesized a pathogenic fibrinogen/fibrin turnover in the disease. The 
evaluation of fibrinolysis in DH is justified also by the observed extravascular 
deposition of fibrin and fibrinogen in the papillary dermis of DH skin confirmed by 
several laboratories. These fibrin deposits are characteristic for the disease and 
appeared at an early stage of blister formation [[6], [7], [8]]. DH skin lesions had 
been initiated in vivo by autologous serum injection, but this reaction did not 
develop in response to plasma treated with heparin or an antifibrinolytic agent (-
aminocaproic acid) [21]. Some reports evidence the efficiency of heparin in the 
treatment of severe DH patients, who did not tolerate sulfones [[22], [23], [24]], but 
the exact mechanism behind this therapeutic effect has not been fully explored. 
 
Our present study addressed the formation of fibrin, its structure and susceptibility 
to lysis in DH patients (untreated or treated with dapsone or GFD). The turbidity-
based fibrinolytic assay used by us provides information on all of these aspects of 
fibrin turnover including all essential endogenous components of the system 
(fibrinogen with associated plasma proteins, protease inhibitors, plasminogen). 
Only the triggers of clotting (thrombin) and lysis (tPA) were exogenously added. 
Thus, the parameters gained from this assay can be considered as characteristics 
of the global fibrinolytic potential of plasma. The median lysis time of plasma clots 
from untreated DH patients was more than 3-fold longer in this assay compared to 
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healthy subjects, clearly demonstrating an impaired fibrinolytic potential. The 
second parameter determined in the turbidimetric assay (the maximal turbidity, 
A340max) is related to fibrin structure [[17], [18]], and the almost 2-fold increase of its 
median values in plasma clots from untreated patients indicated morphological 
alterations that were identified as thicker fibers with SEM evaluation. On their own 
such changes in fibrin structure can form the basis for increased fibrinolytic 
resistance of the clots as we have recently described for other modifiers of fibrin 
assembly (DNA and histones released by neutrophils) which also cause thickening 
of fibers and suppressed tPA-induced lysis [Longstaff 2013, Varjú 2015]. The 
specificity of changes in the fibrin structure and lysis properties for DH pathology 
was tested in comparison with measurements performed in plasma clots of 
pemphigus vulgaris patients, which did not show such abnormalities. This finding 
does not rule out the possibility for similar fibrinolytic alterations in other blistering 
skin diseases.  
 
When a plasma clot is formed, a broad range of proteins associated with fibrinogen 
is entrapped in its structure [25]. The prevalent cryofibrinogenemia in DH [9] raises 
the possibility that the altered structural and lytic profile of fibrin in DH is due to a 
factor associated with circulating fibrinogen. This hypothesis was confirmed by our 
work with serum samples, in which the fibrinogen (and associated proteins) was 
removed and subsequently substituted with purified human fibrinogen. Such serum 
clots from DH patients did not differ in their fibrinolytic properties from clots of 
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healthy subjects.  
 
Thus, the impaired fibrinolytic potential and the modified fibrin structure were 
associated and could contribute to DH skin lesion initiation, supporting earlier data 
that suggested the role of haemostatic imbalance in cutaneous symptoms and 
highlighted the therapeutic effect of anticoagulation [[20], [21], [22], [24]]. An 
established therapeutic modality in DH is dapsone administration. The favourable 
effect of dapsone on fibrinolysis and fibrin structure in DH evidenced by the present 
study represents a novel aspect of its therapeutic action complementary to 
previously hypothesized mechanisms [26]. In addition, it furthers our understanding 
of dapsone effectiveness in cryofibrinogenemia-associated diseases [10] (Kárpáti 
et al., 1997) and different vasculitis forms [27].  
 
Alterations of fibrinolysis are known to exist in other autoimmune blistering skin 
diseases, e.g. inhibited fibrinolysis was found in active bullous pemphigoid and it 
improved after systemic corticosteroid treatment [28]. In the blood of DH patients a 
significantly lower urokinase plasminogen activator concentration, plasminogen 
level, α2-antiplasmin activity and higher plasminogen activator inhibitor-1 and 
plasmin–α2-antiplasmin complex concentration were demonstrated [29]. Some of 
these changes in the systemic levels of fibrinolytic factors in DH (elevated 
plasminogen activator inhibitor-1, lower plasminogen) are probably related to the 
underlying inflammatory processes and could also contribute to the retarded 
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fibrinolysis revealed by the present study (in addition to the lytic consequences of 
altered fibrin structure). 
 
In summary, we observed a reduced fibrinolytic potential and modified fibrin 
structure of plasma clots in untreated DH, whereas the reduced fibrinolytic potential 
and the structural abnormalities of fibrin were reversed under dapsone treatment. 
The association of active symptomatic skin disease with fibrinolytic abnormalities in 
plasma and the parallel normalization of skin symptoms and clot properties under 
efficient therapy suggest that fibrin(ogen) turnover is involved in the 
pathomechanism of DH. Future elucidation of the mechanistic contribution of fibrin 
and cryofibrinogen to the progress of the local skin lesions could delineate new 
avenues for therapeutic intervention in DH.  
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LEGENDS 
 
Fig. 1. Formation and dissolution of plasma (A) and serum (B) clots monitored by 
turbidity. Tissue-type plasminogen activator was added to anticoagulated plasma 
or to serum supplemented with fibrinogen, and clotting was initiated with thrombin 
and Ca2+. The absorbance was continuously monitored at 340 nm (A340) as an 
indicator of clot formation (ascending phase up to A340max) and lysis (descending 
phase). The lysis time - defined as the time needed to reduce the turbidity of the 
clot to half-maximal value - was used as a quantitative parameter of fibrinolytic 
activity, whereas the A340max as an indicator of fibrin structure. Each curve was 
generated as the mean value of eight parallel measurements. Data for untreated 
DH patients are shown with continuous lines, whereas dashed lines are used for 
DH patients under treatment. P1, P2 and P3 indicate the patients 1, 2 and 3 (see 
Table 1) selected for evaluation of their plasma clot ultrastructure. 
 
Fig. 2. Quantitative assessment of the fibrinolytic potential of plasma (2A, 2C) and 
serum (2B, 2D) clots. Lysis time and A340max were derived from the experimental 
setup shown in Fig. 1. Each symbol represents the mean value of eight 
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independent experiments from a single sample (p values refer to Kolmogorov-
Smirnov test for data distribution in the total, dapsone and gluten-free diet (GFD) 
treated and untreated groups of DH patients compared to healthy subjects as well 
as dapsone and GFD treated patients to untreated patients). 
 
Fig. 3. Ultrastructure of clot fibrin network by scanning electron microscopy (SEM). 
(A) Plasma clots were examined after 30 min clotting (scale bar = 1µm). Patient (P) 
samples were selected based on their fibrinolytic profiles shown in Figure 1: P1, a 
TG2-TG3 antibody positive, untreated patient; P2, a TG2-TG3 antibody negative, 
dapsone treated patient, under gluten-free diet; P3, a TG2 antibody negative-TG3 
antibody positive, only dapsone treated patient. (B) Diameter of 300 fibers was 
measured and their empirical (black histograms) as well as best-fitted theoretical 
(gray curves) probability density functions (PDF) were determined. Median values 
and interquartile range are shown for theoretical distributions of diameter values 
(see Materials and Methods). 
 
 
 
 
 
TABLES AND FIGURES 
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Table 1. Summary of clinical and laboratory data of DH patients (n=23) by the 
turbidimetric clot lysis-assay and as a separate set, data of pemphigus vulgaris 
patients (n=5). 
 
Patients Age/ 
Sex 
Duration 
of DH/ 
pemphigu
s vulgaris 
Skin 
sympto
m1 
GFD Dapson
e 
EMA anti-TG2 
IgA ELISA 
(AU/ml)2 
anti-TG3 
IgA 
ELISA 
(AU/ml)3 
Cryo-
protein 
 
Lysis 
time in 
plasma/ 
serum 
(min)4 
A340 
in 
plasma/
serum4 
1 = P1 31/F 6y Yes No No Pos >100 235 Neg 39.5/ 
58.6 
0.634/ 
0.191 
2 = P2 26/F 8y Yes Yes Yes Neg <10 20 Neg 20.6/ 
73.7 
0.202/ 
0.316 
3 = P3 44/M 33y No No Yes Pos <10 33 CF ++ 35.2/ 
100.5 
0.314/ 
0.262 
4  36/M 1y Yes No No Neg <10 20 Neg 121.1/ 
88.2 
0.345/ 
0.239 
5  30/F 25y No Yes No Neg <10 15 Neg 93.3/ 
69.5 
0.409/ 
0.268 
6 29/M 23y No Yes No Neg <10 10 CF + 31.0/ 
82.7 
0.495/ 
0.251 
7 27/F 23y No Yes No Neg <10 5 CF + 35.2/ 
41.4 
0.561/ 
0.261 
8 21/M 15y No Yes No Neg <10 9 Neg 31.0/ 
45.4 
0.387/ 
0.251 
9 60/M 10y No Yes No Neg <10 20 CF + 38.6/ 
92.1 
0.318/ 
0.265 
10 29/M 6y No Yes No Neg <10 2 Neg 50.1/ 
64.3 
0.361/ 
0.273 
11 27/M 24y No Yes No Neg <10 8 Neg 56.6/ 
82.2 
0.387/ 
0.241 
12 26/M 5y No Yes No Neg <10 1 Neg 46.0/ 
66.3 
0.350/ 
0.172 
13 61/M 1y No Yes Yes Neg <10 35 Neg 29.5/ 
78.7 
0.301/ 
0.247 
14 64/F 8y Yes No Yes Neg <10 15 Neg 30.8/ 
53.4 
0.452/ 
0.272 
15 23/M 17y No Yes No Neg <10 8 Neg 31.4/ 
152.9 
0.312/ 
0.224 
16 43/M 23y Yes Yes Yes Neg <10 15 Neg 38.4/ 
97.1 
0.352/ 
0.282 
17 45/M 1y Yes Yes No Neg <10 20 CF + 31.8/ 
76.5 
0.302/ 
0.241 
18 44/M 37y Yes No No Pos >100 80 
CF ++, 
CG + 
55.8/ 
51.3 
0.437/ 
0.220 
19 49/M 1y Yes No No Neg <10 16 Neg 103.5/ 
69.6 
0.418/ 
0.219 
20 40/F 31y No Yes No Neg <10 5 Neg 42.4/ 
65.5 
0.382/ 
0.278 
21 44/M 5y Yes No No Pos >100 103 CF + 25.4/ 
66.8 
0.275/ 
0.208 
22 74/M 1y Yes No No Pos >100 >200 Neg 98.8/ 
33.4 
0.542/ 
0.272 
23 68/M 6m Yes No No Neg 22 77 Neg 79.3/ 
31.6 
0.424/ 
0.256 
PV1 66/F 4m Yes No No Neg <10 2 NA 111.3/ 
52.8 
0.455/ 
0.297 
PV2 74/F 1m Yes No No Neg <10 5 NA 116.2/ 
56.2 
0.537/ 
0.240 
PV3 41/F 2m Yes No No Neg <10 1 NA 78/3 
32.6 
0.343/ 
0.249 
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PV4 49/F 2m Yes No No Neg <10 4 NA 112.5/ 
63.9 
0.319/ 
0.251 
PV5 60/F 2m Yes No No Neg <10 1 NA 97.3/ 
75.2 
0.460/ 
0.236 
 
Abbreviations: A340, light absorbance value at 340 nm; CF, cryofibrinogen; CG, 
cryoglobulin; DH, dermatitis herpetiformis; ELISA, enzyme-linked immunosorbent 
assay; EMA, endomysial antibodies; F, female; GFD, gluten-free diet; IgA, 
immunoglobulin A; y, year; m, month; M, male; NA, not available; Neg, negative; 
Pos, positive; TG, transglutaminase  
1 At the time of blood sample collection. 
2 positive: >10 AU/ml, negative: ≤10 AU/ml 
3 positive: >22 AU/ml, negative: ≤ 22 AU/ml 
4 Plasma / serum samples were examined by turbidimetric clot-lysis assay. Serum 
samples were supplemented with purified human fibrinogen. 
 
 
 
Table 2. Direct effect of dapsone on the fibrinolytic parameters of plasma from 
untreated DH patients.  Dapsone at 5 µg/ml was applied to plasma samples of 2 
untreated DH patients (S1, S2) for 30 min prior the clotting in the fibrinolytic assay 
performed as described in Fig. 1A. Maximal turbidity (A340max) and lysis time values 
are presented as mean ± SD, n=8. Asterisk indicates significant difference between 
the parameters of the dapsone-treated and the respective native plasma clots  at 
p<0.05 according to Kolmogorov-Smirnov test.   
 
 A340max lysis time (min) 
 no additive +dapsone no additive +dapsone 
S1 0.542±0.038 0.501*±0.018 96.81±9.14 85.53*±4.65 
S2 0.424±0.014 0.384*±0.013 79.28±3.48 75.09*±2.25 
 
 



